Early versus late BCG vaccination in HIV-1-exposed infants in Uganda: study protocol for a randomized controlled trial

Victoria Nankabirwa, James K Tumwine, Olive Namugga, Thorkild Tylleskär, Grace Ndeezi, Bjarne Robberstad, Mihai G Netea, Halvor Sommerfelt, Victoria Nankabirwa, James K Tumwine, Olive Namugga, Thorkild Tylleskär, Grace Ndeezi, Bjarne Robberstad, Mihai G Netea, Halvor Sommerfelt

Abstract

Background: Bacillus Calmette-Guérin (BCG) vaccination may have nonspecific effects, i.e., effects on childhood morbidity and mortality that go beyond its effect on the risk of childhood tuberculosis (TB). Though the available scientific literature is mostly from observational studies, and is fraught with controversy, BCG vaccination at birth may protect infants in high-mortality populations against serious infections other than TB. Yet, other studies indicate that giving BCG later in infancy may modify immune responses to non-TB antigens and potentially enhance immunity, potentially also against tuberculosis (TB). It is unclear whether BCG vaccination very early in life offers adequate protection against TB and other infections among HIV-1-exposed children because even those who remain uninfected with HIV-1 show signs of impaired immunocompetence early in infancy. This study will compare BCG vaccination at birth with BCG vaccination at 14 weeks of age in HIV-1-exposed infants.

Methods: This is an individually randomized controlled trial in 2200 HIV-1-exposed infants. The intervention is BCG vaccination within 24 h of birth while the comparator is BCG given at 14 weeks of age. The study co-primary outcomes are severe illness in the first 14 weeks of life, and production of tumor necrosis factor, interleukin (IL)-1β, IL-6 and interferon-γ in response to mycobacterial and nonmycobacterial antigens. The study is being conducted in three health centers in Uganda.

Discussion: A well-timed BCG vaccination could have important nonspecific effects in HIV-1-exposed infants. This trial could inform the development of appropriate timing of BCG vaccination for HIV-1-exposed infants.

Trial registration: ClinicalTrials.gov, identifier: NCT02606526 . Registered on 12 November 2015.

Keywords: BCG; Infants HIV-1-exposed; Nonspecific effects; Trial; Vaccination.

Figures

Fig. 1
Fig. 1
Bacille Calmette-Guérin (BCG) trial participant screening, enrollment and follow-up
Fig. 2
Fig. 2
Time schedule for study procedures
Fig. 3
Fig. 3
Flow chart of study participants
Fig. 4
Fig. 4
The decision model

References

    1. Elguero E, Simondon KB, Vaugelade J, Marra A, Simondon F. Non-specific effects of vaccination on child survival? A prospective study in Senegal. Trop Med Int Health. 2005;10(10):956–60. doi: 10.1111/j.1365-3156.2005.01479.x.
    1. Krishnan A, Srivastava R, Dwivedi P, Ng N, Byass P, Pandav CS. Non-specific sex-differential effect of DTP vaccination may partially explain the excess girl child mortality in Ballabgarh, India. Trop Med Int Health. 2013;18(11):1329–37.
    1. Aaby P, Benn CS, Nielsen J, Ravn H. Sex-differential non-specific effects of BCG and DTP in Cebu, The Philippines. Int J Epidemiol. 2009;38(1):320–3. doi: 10.1093/ije/dyn005.
    1. Shann F. The nonspecific effects of vaccines and the expanded program on immunization. J Infect Dis. 2011;204(2):182–4. doi: 10.1093/infdis/jir244.
    1. Shann F. The non-specific effects of vaccines. Arch Dis Child. 2010;95(9):662–7. doi: 10.1136/adc.2009.157537.
    1. Hirve S, Bavdekar A, Juvekar S, Benn CS, Nielsen J, Aaby P. Non-specific and sex-differential effects of vaccinations on child survival in rural western India. Vaccine. 2012;30(50):7300–8. doi: 10.1016/j.vaccine.2012.09.035.
    1. Roth A, Garly ML, Jensen H, Nielsen J, Aaby P. Bacillus Calmette-Guerin vaccination and infant mortality. Expert Rev Vaccines. 2006;5(2):277–93. doi: 10.1586/14760584.5.2.277.
    1. Shann F. Commentary: BCG vaccination halves neonatal mortality. Pediatr Infect Dis J. 2012;31(3):308–9. doi: 10.1097/INF.0b013e3182465be8.
    1. Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Lisse IM, Stensballe L, Diness BR, Lausch KR, Lund N, et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis. 2011;204(2):245–52. doi: 10.1093/infdis/jir240.
    1. Biering-Sorensen S, Aaby P, Napirna BM, Roth A, Ravn H, Rodrigues A, Whittle H, Benn CS. Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guerin vaccination at first health center contact. Pediatr Infect Dis J. 2012;31(3):306–8. doi: 10.1097/INF.0b013e3182458289.
    1. Roth AE, Stensballe LG, Garly ML, Aaby P. Beneficial non-targeted effects of BCG—ethical implications for the coming introduction of new TB vaccines. Tuberculosis (Edinb) 2006;86(6):397–403. doi: 10.1016/j.tube.2006.02.001.
    1. Stensballe LG, Nante E, Jensen IP, Kofoed PE, Poulsen A, Jensen H, Newport M, Marchant A, Aaby P. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. Vaccine. 2005;23(10):1251–7. doi: 10.1016/j.vaccine.2004.09.006.
    1. Jason J, Archibald LK, Nwanyanwu OC, Kazembe PN, Chatt JA, Norton E, Dobbie H, Jarvis WR. Clinical and immune impact of Mycobacterium bovis BCG vaccination scarring. Infect Immun. 2002;70(11):6188–95. doi: 10.1128/IAI.70.11.6188-6195.2002.
    1. Nankabirwa V, Tumwine JK, Mugaba PM, Tylleskar T, Sommerfelt H, Group P-ES. Child survival and BCG vaccination: a community based prospective cohort study in Uganda. BMC Public Health. 2015;15:175. doi: 10.1186/s12889-015-1497-8.
    1. Rousseau MC, Parent ME, St-Pierre Y. Potential health effects from non-specific stimulation of the immune function in early age: the example of BCG vaccination. Pediatr Allergy Immunol. 2008;19(5):438–48. doi: 10.1111/j.1399-3038.2007.00669.x.
    1. Aaby P, Shaheen SO, Heyes CB, Goudiaby A, Hall AJ, Shiell AW, Jensen H, Marchant A. Early BCG vaccination and reduction in atopy in Guinea-Bissau. Clin Exp Allergy. 2000;30(5):644–50. doi: 10.1046/j.1365-2222.2000.00803.x.
    1. Ota MO, van der Sande MA, Walraven GE, Jeffries D, Nyan OA, Marchant A, McAdam KP. Absence of association between delayed type hypersensitivity to tuberculin and atopy in children in The Gambia. Clin Exp Allergy. 2003;33(6):731–6. doi: 10.1046/j.1365-2222.2003.01599.x.
    1. Choi IS, Koh YI. Therapeutic effects of BCG vaccination in adult asthmatic patients: a randomized, controlled trial. Ann Allergy Asthma Immunol. 2002;88(6):584–91. doi: 10.1016/S1081-1206(10)61890-X.
    1. Elliott AM, Nakiyingi J, Quigley MA, French N, Gilks CF, Whitworth JA. Inverse association between BCG immunisation and intestinal nematode infestation among HIV-1-positive individuals in Uganda. Lancet. 1999;354(9183):1000–1. doi: 10.1016/S0140-6736(99)03290-0.
    1. Barreto ML, Rodrigues LC, Silva RC, Assis AM, Reis MG, Santos CA, Blanton RE. Lower hookworm incidence, prevalence, and intensity of infection in children with a Bacillus Calmette-Guerin vaccination scar. J Infect Dis. 2000;182(6):1800–3. doi: 10.1086/317627.
    1. Randall AE, Perez MA, Floyd S, Black GF, Crampin AC, Ngwira B, Pistoni WN, Mulawa D, Sichali L, Mwaungulu L, et al. Patterns of helminth infection and relationship to BCG vaccination in Karonga District, northern Malawi. Trans R Soc Trop Med Hyg. 2002;96(1):29–33. doi: 10.1016/S0035-9203(02)90229-4.
    1. World Health Organization . Global tuberculosis report 2013. Geneva: World Health Organization; 2013.
    1. SAGE Working Group on Non-specific Effects of Vaccines (March 2013 – June 2013). . Accessed 15 Dec 2015.
    1. Fine PE, Williams TN, Aaby P, Kallander K, Moulton LH, Flanagan KL, Smith PG, Benn CS, Working Group on Non-specific Effects of Vaccines Epidemiological studies of the “non-specific effects” of vaccines: I–data collection in observational studies. Trop Med Int Health. 2009;14(9):969–76. doi: 10.1111/j.1365-3156.2009.02301.x.
    1. Farrington CP, Firth MJ, Moulton LH, Ravn H, Andersen PK, Evans S, Working Group on Non-specific Effects of Vaccines Epidemiological studies of the non-specific effects of vaccines: II–methodological issues in the design and analysis of cohort studies. Trop Med Int Health. 2009;14(9):977–85. doi: 10.1111/j.1365-3156.2009.02302.x.
    1. Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. BMJ. 2000;321(7274):1435–8. doi: 10.1136/bmj.321.7274.1435.
    1. Vaugelade J, Pinchinat S, Guiella G, Elguero E, Simondon F. Non-specific effects of vaccination on child survival: prospective cohort study in Burkina Faso. BMJ. 2004;329(7478):1309. doi: 10.1136/bmj.38261.496366.82.
    1. Kandasamy R, Voysey M, McQuaid F, de Nie K, Ryan R, Orr O, Uhlig U, Sande C, O’Connor D, Pollard AJ. Non-specific immunological effects of selected routine childhood immunisations: systematic review. BMJ. 2016;355:i5225. doi: 10.1136/bmj.i5225.
    1. Higgins JP, Soares-Weiser K, Lopez-Lopez JA, Kakourou A, Chaplin K, Christensen H, Martin NK, Sterne JA, Reingold AL. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016;355:i5170. doi: 10.1136/bmj.i5170.
    1. Wilson CB. Applying contemporary immunology to elucidate heterologous effects of infant vaccines and to better inform maternal-infant immunization practices. Front Immunol. 2015;6:64. doi: 10.3389/fimmu.2015.00064.
    1. Netea MG, Quintin J, van der Meer JW. Trained immunity: a memory for innate host defense. Cell Host Microbe. 2011;9(5):355–61. doi: 10.1016/j.chom.2011.04.006.
    1. Saeed S, Quintin J, Kerstens HH, Rao NA, Aghajanirefah A, Matarese F, Cheng SC, Ratter J, Berentsen K, van der Ent MA, et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science. 2014;345(6204):1251086. doi: 10.1126/science.1251086.
    1. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, Jacobs C, van Loenhout J, de Jong D, Stunnenberg HG, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A. 2012;109(43):17537–42. doi: 10.1073/pnas.1202870109.
    1. Selin LK, Varga SM, Wong IC, Welsh RM. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J Exp Med. 1998;188(9):1705–15. doi: 10.1084/jem.188.9.1705.
    1. Mazzola TN, da Silva MT, Abramczuk BM, Moreno YM, Lima SC, Zorzeto TQ, Passeto AS, Vilela MM. Impaired Bacillus Calmette-Guerin cellular immune response in HIV-exposed, uninfected infants. AIDS. 2011;25(17):2079–87. doi: 10.1097/QAD.0b013e32834bba0a.
    1. Hesseling AC, Cotton MF, Fordham von Reyn C, Graham SM, Gie RP, Hussey GD. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis. 2008;12(12):1376–9.
    1. Hesseling AC, Caldwell J, Cotton MF, Eley BS, Jaspan HB, Jennings K, Marais BJ, Nuttall J, Rabie H, Roux P, et al. BCG vaccination in South African HIV-exposed infants—risks and benefits. S Afr Med J. 2009;99(2):88–91.
    1. Miles DJ, Gadama L, Gumbi A, Nyalo F, Makanani B, Heyderman RS. Human immunodeficiency virus (HIV) infection during pregnancy induces CD4 T-cell differentiation and modulates responses to Bacille Calmette-Guerin (BCG) vaccine in HIV-uninfected infants. Immunology. 2010;129(3):446–54. doi: 10.1111/j.1365-2567.2009.03186.x.
    1. Ota MO, O’Donovan D, Marchant A, Yamuah L, Harding E, Jaffar S, McAdam KP, Corrah T, Whittle H. HIV-negative infants born to HIV-1 but not HIV-2-positive mothers fail to develop a Bacillus Calmette-Guerin scar. AIDS. 1999;13(8):996–8. doi: 10.1097/00002030-199905280-00020.
    1. Msellati P, Dabis F, Lepage P, HItimana DG, Van goethem C, Van De Perre P. BCG vaccination and pediatric HIV infection—Rwanda, 1988-1990. MMWR. 1991;40(48):833–6.
    1. Garly ML, Martins CL, Bale C, Balde MA, Hedegaard KL, Gustafson P, Lisse IM, Whittle HC, Aaby P. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG? Vaccine. 2003;21(21-22):2782–90. doi: 10.1016/S0264-410X(03)00181-6.
    1. Clerici M, Saresella M, Colombo F, Fossati S, Sala N, Bricalli D, Villa ML, Ferrante P, Dally L, Vigano A. T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood. 2000;96(12):3866–71.
    1. Nielsen SD, Jeppesen DL, Kolte L, Clark DR, Sorensen TU, Dreves AM, Ersboll AK, Ryder LP, Valerius NH, Nielsen JO. Impaired progenitor cell function in HIV-negative infants of HIV-positive mothers results in decreased thymic output and low CD4 counts. Blood. 2001;98(2):398–404. doi: 10.1182/blood.V98.2.398.
    1. Embree J, Bwayo J, Nagelkerke N, Njenga S, Nyange P, Ndinya-Achola J, Pamba H, Plummer F. Lymphocyte subsets in human immunodeficiency virus type 1-infected and uninfected children in Nairobi. Pediatr Infect Dis J. 2001;20(4):397–403. doi: 10.1097/00006454-200104000-00006.
    1. Chougnet C, Kovacs A, Baker R, Mueller BU, Luban NL, Liewehr DJ, Steinberg SM, Thomas EK, Shearer GM. Influence of human immunodeficiency virus-infected maternal environment on development of infant interleukin-12 production. J Infect Dis. 2000;181(5):1590–7. doi: 10.1086/315458.
    1. Kuhn L, Coutsoudis A, Moodley D, Mngqundaniso N, Trabattoni D, Shearer GM, Clerici M, Coovadia HM. Interferon-gamma and interleukin-10 production among HIV-1-infected and uninfected infants of HIV-1-infected mothers. Pediatr Res. 2001;50(3):412–6. doi: 10.1203/00006450-200109000-00018.
    1. Levy JA, Hsueh F, Blackbourn DJ, Wara D, Weintrub PS. CD8 cell noncytotoxic antiviral activity in human immunodeficiency virus-infected and -uninfected children. J Infect Dis. 1998;177(2):470–2. doi: 10.1086/517378.
    1. Kagina BM, Abel B, Bowmaker M, Scriba TJ, Gelderbloem S, Smit E, Erasmus M, Nene N, Walzl G, Black G, et al. Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. Vaccine. 2009;27(40):5488–95. doi: 10.1016/j.vaccine.2009.06.103.
    1. Blakney AK, Tchakoute CT, Hesseling AC, Kidzeru EB, Jones CE, Passmore JA, Sodora DL, Gray CM, Jaspan HB. Delayed BCG vaccination results in minimal alterations in T cell immunogenicity of acellular pertussis and tetanus immunizations in HIV-exposed infants. Vaccine. 2015;33(38):4782–9. doi: 10.1016/j.vaccine.2015.07.096.
    1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. 2010.
    1. AIDS Epidemic Update, Regional Summary: Sub-Saharan Africa. . Accessed 20 Jan 2014.
    1. Mofenson LM. Advances in the prevention of vertical transmission of human immunodeficiency virus. Semin Pediatr Infect Dis. 2003;14(4):295–308. doi: 10.1053/j.spid.2003.09.003.
    1. Agangi A, Thorne C, Newell ML. Increasing likelihood of further live births in HIV-infected women in recent years. BJOG. 2005;112(7):881–8. doi: 10.1111/j.1471-0528.2005.00569.x.
    1. Filteau S. The HIV-exposed, uninfected African child. Trop Med Int Health. 2009;14(3):276–87. doi: 10.1111/j.1365-3156.2009.02220.x.
    1. Afran L, Garcia Knight M, Nduati E, Urban BC, Heyderman RS, Rowland-Jones SL. HIV-exposed uninfected children: a growing population with a vulnerable immune system? Clin Exp Immunol. 2014;176(1):11–22. doi: 10.1111/cei.12251.
    1. Slogrove A, Reikie B, Naidoo S, De Beer C, Ho K, Cotton M, Bettinger J, Speert D, Esser M, Kollmann T. HIV-exposed uninfected infants are at increased risk for severe infections in the first year of life. J Trop Pediatr. 2012;58(6):505–8.
    1. Slogrove AL, Cotton MF, Esser MM. Severe infections in HIV-exposed uninfected infants: clinical evidence of immunodeficiency. J Trop Pediatr. 2010;56(2):75–81. doi: 10.1093/tropej/fmp057.
    1. Taron-Brocard C, Le Chenadec J, Faye A, Dollfus C, Goetghebuer T, Gajdos V, Labaune JM, Perilhou A, Mandelbrot L, Blanche S, et al. Increased risk of serious bacterial infections due to maternal immunosuppression in HIV-exposed uninfected infants in a European country. Clin Infect Dis. 2014;59(9):1332–45. doi: 10.1093/cid/ciu586.
    1. Heresi GP, Caceres E, Atkins JT, Reuben J, Doyle M. Pneumocystis carinii pneumonia in infants who were exposed to human immunodeficiency virus but were not infected: an exception to the AIDS surveillance case definition. Clin Infect Dis. 1997;25(3):739–40. doi: 10.1086/516938.
    1. Adhikari M, Kauchali S, Moodley A. Clinical profile and morbidity pattern of infants born to HIV infected mothers in Durban South Africa. Indian Pediatr. 2006;43(9):804–8.
    1. von Mollendorf C, von Gottberg A, Tempia S, Meiring S, de Gouveia L, Quan V, Lengana S, Avenant T, du Plessis N, Eley B, et al. Increased risk for and mortality from invasive pneumococcal disease in HIV-exposed but uninfected infants aged <1 year in South Africa, 2009-2013. Clin Infect Dis. 2015;60(9):1346–56.
    1. Izadnegahdar R, Fox MP, Jeena P, Qazi SA, Thea DM. Revisiting pneumonia and exposure status in infants born to HIV-infected mothers. Pediatr Infect Dis J. 2014;33(1):70–2. doi: 10.1097/INF.0b013e31829f0ade.
    1. Manicklal S, van Niekerk AM, Kroon SM, Hutto C, Novak Z, Pati SK, Chowdhury N, Hsiao NY, Boppana SB. Birth prevalence of congenital cytomegalovirus among infants of HIV-infected women on prenatal antiretroviral prophylaxis in South Africa. Clin Infect Dis. 2014;58(10):1467–72. doi: 10.1093/cid/ciu096.
    1. Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics. 1978;61(1):35–41.
    1. Kuhn L, Kasonde P, Sinkala M, Kankasa C, Semrau K, Scott N, Tsai WY, Vermund SH, Aldrovandi GM, Thea DM. Does severity of HIV disease in HIV-infected mothers affect mortality and morbidity among their uninfected infants? Clin Infect Dis. 2005;41(11):1654–61. doi: 10.1086/498029.
    1. Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Jacobs C, Xavier RJ, van der Meer JW, van Crevel R, Netea MG. BCG-induced trained immunity in NK cells: role for non-specific protection to infection. Clin Immunol. 2014;155(2):213–9. doi: 10.1016/j.clim.2014.10.005.
    1. Tylleskar T, Jackson D, Meda N, Engebretsen IM, Chopra M, Diallo AH, Doherty T, Ekstrom EC, Fadnes LT, Goga A, et al. Exclusive breastfeeding promotion by peer counsellors in sub-Saharan Africa (PROMISE-EBF): a cluster-randomised trial. Lancet. 2011;378(9789):420–7. doi: 10.1016/S0140-6736(11)60738-1.
    1. World Health Organization . WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. Geneva: World Health Organization; 2006. p. 312.
    1. World Health Organization. Good clinical laboratory practice (GCLP). Geneva: World Health Organization; 2009.
    1. Cummings P. Methods for estimating adjusted risk ratios. Stata J. 2009;9(2):175–96.
    1. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005;162(3):199–200. doi: 10.1093/aje/kwi188.
    1. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702–6. doi: 10.1093/aje/kwh090.
    1. The DAMOCLES Study Group A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet. 2005;365(9460):711–22. doi: 10.1016/S0140-6736(05)70939-9.
    1. Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, Elbourne DR, McLeer SK, Parmar MK, Pocock SJ, et al. Issues in data monitoring and interim analysis of trials. Health Technol Assess. 2005;9(7):1–238. doi: 10.3310/hta9070.
    1. Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2011;7:CD003510.
    1. Rieder HL. Opportunity for exposure and risk of infection: the fuel for the tuberculosis pandemic. Infection. 1995;23(1):1–3. doi: 10.1007/BF01710048.
    1. Kesho Bora Study G, de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011;11(3):171–80. doi: 10.1016/S1473-3099(10)70288-7.
    1. Bernatowska EA, Wolska-Kusnierz B, Pac M, Kurenko-Deptuch M, Zwolska Z, Casanova JL, Piatosa B, van Dongen J, Roszkowski K, Mikoluc B, et al. Disseminated bacillus Calmette-Guerin infection and immunodeficiency. Emerg Infect Dis. 2007;13(5):799–801. doi: 10.3201/eid1305.060865.
    1. Rules and Procedures. . Accessed 23 June 2014.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner